Climara shortage: What providers and prescribers need to know in 2026

Climara Supply Disruption: Clinical Overview for Providers

Climara (estradiol transdermal system, Bayer HealthCare Pharmaceuticals) has experienced intermittent supply disruptions affecting pharmacies nationwide. As a once-weekly estradiol patch available in six strengths (0.025 mg/day through 0.1 mg/day), Climara is a cornerstone of transdermal hormone replacement therapy for many patients. This article provides prescribers with a current overview of the supply situation, therapeutic alternatives, and clinical considerations for patient management during the shortage.

Current Supply Status

As of February 2026, Climara continues to face availability challenges at retail pharmacies. The shortage is not consistently reflected on the FDA Drug Shortage Database, which relies on manufacturer-reported data. However, the clinical reality — confirmed by pharmacist reports and patient feedback — is that certain strengths, particularly the 0.05 mg/day and 0.075 mg/day doses, remain difficult to source in many markets.

The underlying causes include:

• Limited manufacturing infrastructure: Climara is produced by 3M Drug Delivery Systems under contract with Bayer. Transdermal patch manufacturing requires specialized facilities, and production capacity has not kept pace with demand.
• Increased HRT prescribing: Prescribing rates for estradiol-containing HRT products have risen significantly, driven by updated clinical guidelines and greater patient awareness of menopausal hormone therapy benefits.
• Supply chain fragility: Specialized raw materials (adhesive matrices, backing films, active pharmaceutical ingredient supply) remain subject to periodic disruption.

Clinical Impact

Interruptions in estradiol therapy can result in rapid recurrence of vasomotor symptoms, with patients reporting return of hot flashes and night sweats within 48 to 72 hours of a missed dose. For patients using Climara for osteoporosis prevention, sustained gaps in therapy may compromise bone mineral density maintenance.

Additionally, patients who have been stable on a specific Climara strength may experience symptom variability if switched to a different formulation or delivery system, necessitating monitoring and potential dose adjustment.

Therapeutic Alternatives

When Climara is unavailable, the following therapeutically equivalent or clinically appropriate alternatives should be considered:

Generic Estradiol Transdermal Patches

AB-rated generic estradiol transdermal patches are the most direct substitution. Multiple manufacturers (Mylan, Noven, others) produce generic weekly and twice-weekly patches. Pharmacists can substitute generics for Climara unless the prescription specifies "dispense as written." Generic patches typically cost patients $25 to $60 per box of 4 patches versus $130 to $200 for brand-name Climara.

Twice-Weekly Estradiol Patches

• Vivelle-Dot (Noven): Available in 0.025, 0.0375, 0.05, 0.075, and 0.1 mg/day. Requires twice-weekly application. Generics available (Dotti).
• Minivelle (Noven): Smallest available estradiol patch. Same strengths and application frequency as Vivelle-Dot.

When converting from a weekly patch to a twice-weekly patch, the daily delivery rate remains the primary dosing parameter. A patient on Climara 0.05 mg/day should be transitioned to a twice-weekly patch delivering 0.05 mg/day.

Estradiol Gels and Sprays

• Divigel (estradiol gel 0.1%): Single-dose packets, applied daily to the thigh. Available in 0.25, 0.5, and 1.0 mg doses.
• EstroGel (estradiol gel 0.06%): Metered-dose pump, applied daily to one arm. Each pump actuation delivers 0.75 mg estradiol.
• Evamist (estradiol spray): 1 to 3 sprays daily to the inner forearm.

Transdermal gels and sprays maintain the benefit of avoiding first-pass hepatic metabolism, which may be relevant for patients at elevated thrombotic risk.

Oral Estradiol

Oral estradiol (0.5 mg, 1 mg, 2 mg tablets) is the most widely available and affordable option, with costs as low as $4 to $15 per month. However, oral administration involves first-pass hepatic metabolism, which may increase hepatic protein synthesis (including clotting factors) and carries a potentially higher venous thromboembolism risk relative to transdermal delivery. This should be weighed in the clinical context, particularly for patients with obesity, thrombophilia history, or advanced age.

Prescribing Recommendations During the Shortage

1. Allow generic substitution: Unless there is a specific clinical reason to require brand-name Climara, ensure prescriptions permit generic estradiol patch substitution.
2. Specify alternative formulations: If writing a new prescription, consider specifying that the pharmacist may dispense any AB-rated estradiol transdermal product.
3. Proactive patient communication: Inform patients of the supply situation and discuss backup options before they run out. Patients who are aware of alternatives in advance are less likely to experience treatment interruptions.
4. Monitor after switching: If switching patients to a different delivery system (patch to gel, or transdermal to oral), consider checking serum estradiol levels 4 to 8 weeks after the change to confirm adequate dosing.
5. Leverage MedFinder for patients: Direct patients to MedFinder to locate pharmacies with current stock. For provider-specific tools, visit medfinder.com/providers.

Patient Assistance and Cost Considerations

Switching products during a shortage can create cost confusion for patients. Key points to communicate:

• Generic estradiol patches are typically covered at preferred-tier copays by most insurance plans
• Brand-name alternatives (Vivelle-Dot, Minivelle) may require higher copays or prior authorization
• Bayer Patient Assistance Foundation (1-866-575-5002) offers free medication for qualifying uninsured or underinsured patients
• Coupon cards from SingleCare, GoodRx, and other platforms can reduce out-of-pocket costs for generic patches to as low as $25 per box

For comprehensive cost information, see our provider's guide to helping patients save on Climara.

Resources for Providers

• MedFinder for Providers — Help patients locate Climara and alternatives in stock
• How to help patients find Climara in stock — Practical provider guide
• Patient-facing shortage update — Share with patients
• FDA Drug Shortage Database